Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

KIDS vs IART: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IART Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

IART Overall Winner 6-Pillar Tally: KIDS 1 – 5 IART Matrix Metrics: KIDS 2 – 8 IART

As of Nov 19, 2026, Integra LifeSciences Holdings (IART) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). KIDS carries a Unified Composite Score of 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin), whereas IART carries 48.5/100 (HOLD) at $13.55 (5.7x Forward P/E, 9.9% operating margin).

  • Growth vs. Quality Trade-Off: IART earns the overall head-to-head edge with a stronger Unified Composite Score (48.5/100 HOLD vs. KIDS 45.1/100 HOLD) and 1.57β · 61% Vol risk profile, whereas KIDS leads top-line expansion (+18.6% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: KIDS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 64.2); meanwhile IART is in a Breakdown options structure phase (RSI 47.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KIDS vs IART
KIDS NASDAQ
OrthoPediatrics Corp. Common Stock
Surgical & Medical Instruments & Apparatus
$32.51
+2.72% 1D
Market Cap $850.2M
TTM Revenue $264M
Forward P/E N/M
Beta / 30D Vol 0.81β · 108% Vol
Unified Composite Score
45.1 / 100 HOLD
Tech 28.0 Fund 40.0 Flow 50.0 Mom 46.3
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (12.1% over 20 days), RSI 64
RSI-14: 64.2 · SMA20: $30.90 · SMA50: $25.86
IART NASDAQ Head-to-Head Winner
Integra LifeSciences Holdings
Surgical & Medical Instruments & Apparatus
$13.55
-2.24% 1D
Market Cap $1.1B
TTM Revenue $1.66B
Forward P/E 5.7x
Beta / 30D Vol 1.57β · 61% Vol
Unified Composite Score
48.5 / 100 HOLD
Tech 37.0 Fund 47.0 Flow 64.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.3 · SMA20: $13.54 · SMA50: $14.13

6-Pillar Scorecard Institutional Category Breakdown (KIDS 1 – 5 IART)

Columns: Metric · KIDS · IART
1. Valuation Multiples IART
Forward P/E N/M 5.7x
Trailing P/E N/M 81.5x
PEG Ratio N/M 0.71x
EV / Revenue 3.2x 0.6x
2. Growth & Scale IART
Revenue Growth (YoY) +18.6% +2.3%
Earnings Growth (YoY) +0.0% +0.4%
TTM Revenue (USD) $264M $1.66B
Market Cap $850.2M $1.1B
3. Profitability & Quality IART
Gross Margin 73.8% 55.5%
Operating Margin -8.2% 9.9%
Net Profit Margin -12.8% 0.8%
Return on Equity (ROE) -9.8% 1.2%
4. Balance Sheet & Cash Flow IART
Cash Generation (TTM) $1.1M EBITDA $72M
Cash Flow Margin 0.4% EBITDA Mgn 4.3%
Net Cash / Leverage $12.99 Book/Sh · -9.8% ROE $77M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IART
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 145.1% (100th %ile) 57.4% (16th %ile)
Put/Call OI Skew N/A 0.92x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat KIDS
OpEx & R&D Intensity 82.0% of Rev ($217M) 45.6% of Rev ($755M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KIDS (2) vs IART (8)
Institutional Metric KIDS IART Criterion Row Edge
Market Capitalization
Scale
$850.2M $1.1B Larger Scale IART
Trailing P/E Ratio
Valuation
N/M 81.5x Lower Multiple IART
Forward P/E Ratio
Valuation
N/M 5.7x Lower Multiple IART
Revenue Growth (YoY)
Growth
+18.6% +2.3% Higher Growth KIDS
Operating Margin (TTM)
Profitability
-8.2% 9.9% Higher Margin IART
Net Profit Margin
Profitability
-12.8% 0.8% Higher Margin IART
Return on Equity (ROE)
Capital Efficiency
-9.8% 1.2% Higher ROE IART
52-Week Range Position
Momentum
90% ($14–$35) 41% ($9–$20) Stronger Trend KIDS
Beta / 30D Volatility
Risk Regime
0.81β · 108% Vol 1.57β · 61% Vol Lower Realized Risk IART
Unified Institutional Score
Composite Signal
45.1 / 100 (HOLD) 48.5 / 100 (HOLD) Higher Composite IART
Trailing 12M Revenue (USD)
Operating Scale
$264M $1.66B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
73.8% 55.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.2x EV/Rev 0.71x PEG · 0.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.1M EBITDA ($12.99 Book/Sh · -9.8% ROE) $72M ($77M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KIDS +21.93 pp
KIDS: +36.37% · IART: +14.44%
3M Horizon KIDS +45.8 pp
KIDS: +26.74% · IART: -19.06%
6M Horizon KIDS +86.78 pp
KIDS: +76.4% · IART: -10.38%
1Y Horizon KIDS +80.19 pp
KIDS: +98.84% · IART: +18.65%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KIDS vs IART. Trailing 12-month operating profitability (KIDS -8.2% vs IART 9.9%) and valuation multiples (KIDS N/M vs IART 5.7x Forward P/E) are benchmarked directly in Pillar 4 below.

KIDS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$264M
Gross Margin73.8%
Op. Margin-8.2%
ROE / Fwd P/E-9.8% · N/M
IART ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.66B
Gross Margin55.5%
Op. Margin9.9%
ROE / Fwd P/E1.2% · 5.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KIDS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 145.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KIDS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IART BREAKDOWN
102d in phase · OBV NEUTRAL
Current IV 57.4%
IV Percentile 16th %ile
Put/Call OI Skew 0.92x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact IART Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KIDS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $850.2M market capitalization and -8.2% operating margin.
OpEx & R&D Reinvestment 82.0% of Rev ($217M)
90D Engineering Disclosures 0 Published
IART Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.1B market capitalization and 9.9% operating margin.
OpEx & R&D Reinvestment 45.6% of Rev ($755M)
90D Engineering Disclosures 0 Published

Investor FAQ KIDS vs IART Key Questions & Quantitative Answers

As of Nov 19, 2026, Integra LifeSciences Holdings (IART) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). KIDS carries a Unified Composite Score of 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin), whereas IART carries 48.5/100 (HOLD) at $13.55 (5.7x Forward P/E, 9.9% operating margin). Growth vs. Quality Trade-Off: IART earns the overall head-to-head edge with a stronger Unified Composite Score (48.5/100 HOLD vs. KIDS 45.1/100 HOLD) and 1.57β · 61% Vol risk profile, whereas KIDS leads top-line expansion (+18.6% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: KIDS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 64.2); meanwhile IART is in a Breakdown options structure phase (RSI 47.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IART leads the Growth & Scale pillar: KIDS posts +18.6% YoY revenue growth and +0.0% YoY earnings growth on $264M TTM revenue (73.8% gross margin, -8.2% operating margin), compared with IART at +2.3% YoY revenue growth and +0.4% YoY earnings growth on $1.66B TTM revenue (55.5% gross margin, 9.9% operating margin). On trailing 12-month operating scale, KIDS generates $264M in USD-normalized revenue versus $1.66B for IART. In operating R&D and SG&A reinvestment, KIDS deploys 82.0% of Rev ($217M) (0 90-day corporate R&D disclosures) versus 45.6% of Rev ($755M) (0 disclosures) for IART.

IART screens cheaper on headline valuation multiples. KIDS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.2x EV/Revenue (0.4% EBITDA margin), whereas IART trades at 5.7x Forward P/E, 81.5x Trailing P/E, 0.71x PEG, and 0.6x EV/Revenue (4.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KIDS (-9.8% ROE) versus IART (1.2% ROE) capital efficiency.

In options market volatility and institutional positioning, KIDS carries 145.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 108% Vol realized risk). By comparison, IART carries 57.4% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.92x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.57β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.